News | 28 May 2012
Research analysts at UBS AG (NYSE: UBS) cut their target price on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) from $60.00 to $52.00 in a report released on Friday. The firm currently has a ?buy? rating on the stock.
Click on the link to read the full article at Daily Political
(This link will open in a new window)